نتایج جستجو برای: releasing hormone agonists
تعداد نتایج: 196829 فیلتر نتایج به سال:
In their review article, Drs. Crawford and Moul seek to describe the cardiovascular (CV), renal, and pulmonary complications associated with the use of long-term androgen deprivation therapy (ADT) in men with prostate cancer.[1] Furthermore, they attempt to determine whether there is a difference in CV and renal complications between different types of ADT, including luteinizing hormone–releasi...
Gonadotropin-releasing hormone agonists (GnRH agonists) are widely recognised as an effective treatment for patients with moderate to severe symptomatic endometriosis. In addition, the role of GnRH antagonists is being explored. GnRH analogues act by modifying the release of follicle-stimulating hormone (FSH) and luteinising hormone (LH), thereby suppressing ovarian estradiol production. GnRH a...
The dismal prognosis of malignant brain tumors drives the development of new treatment modalities. In view of the multiple activities of growth hormone-releasing hormone (GHRH), we hypothesized that pretreatment with a GHRH agonist, JI-34, might increase the susceptibility of U-87 MG glioblastoma multiforme (GBM) cells to subsequent treatment with the cytotoxic drug, doxorubicin (DOX). This con...
Prostate cancer is linked to the male sex hormone testosterone. In advanced disease, blocking the production of testosterone using androgen deprivation therapy causes regression of prostate cancer and minimises or prevents symptoms associated with the disease. Luteinising hormone-releasing hormone agonists are commonly used in the management of prostate cancer, however less is known about the r...
Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید